BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 15616034)

  • 1. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
    Obrosova IG; Pacher P; Szabó C; Zsengeller Z; Hirooka H; Stevens MJ; Yorek MA
    Diabetes; 2005 Jan; 54(1):234-42. PubMed ID: 15616034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.
    Drel VR; Pacher P; Stevens MJ; Obrosova IG
    Free Radic Biol Med; 2006 Apr; 40(8):1454-65. PubMed ID: 16631535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.
    Drel VR; Pacher P; Ali TK; Shin J; Julius U; El-Remessy AB; Obrosova IG
    Int J Mol Med; 2008 Jun; 21(6):667-76. PubMed ID: 18506358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats.
    Obrosova IG; Minchenko AG; Vasupuram R; White L; Abatan OI; Kumagai AK; Frank RN; Stevens MJ
    Diabetes; 2003 Mar; 52(3):864-71. PubMed ID: 12606532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fidarestat and alpha-lipoic acid on diabetes-induced epineurial arteriole vascular dysfunction.
    Yorek MA; Coppey LJ; Gellett JS; Davidson EP; Lund DD
    Exp Diabesity Res; 2004; 5(2):123-35. PubMed ID: 15203883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.
    Coppey LJ; Gellett JS; Davidson EP; Dunlap JA; Yorek MA
    Int J Exp Diabetes Res; 2002; 3(1):21-36. PubMed ID: 11900277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
    Li F; Szabó C; Pacher P; Southan GJ; Abatan OI; Charniauskaya T; Stevens MJ; Obrosova IG
    Diabetologia; 2004 Apr; 47(4):710-7. PubMed ID: 15298348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve.
    Coppey LJ; Gellett JS; Davidson EP; Dunlap JA; Lund DD; Yorek MA
    Diabetes; 2001 Aug; 50(8):1927-37. PubMed ID: 11473057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.
    Kuzumoto Y; Kusunoki S; Kato N; Kihara M; Low PA
    Diabetologia; 2006 Dec; 49(12):3085-93. PubMed ID: 17063327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.
    Obrosova IG; Drel VR; Pacher P; Ilnytska O; Wang ZQ; Stevens MJ; Yorek MA
    Diabetes; 2005 Dec; 54(12):3435-41. PubMed ID: 16306359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve.
    Coppey LJ; Davidson EP; Dunlap JA; Lund DD; Yorek MA
    Int J Exp Diabetes Res; 2000; 1(2):131-43. PubMed ID: 11469397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
    Ho EC; Lam KS; Chen YS; Yip JC; Arvindakshan M; Yamagishi S; Yagihashi S; Oates PJ; Ellery CA; Chung SS; Chung SK
    Diabetes; 2006 Jul; 55(7):1946-53. PubMed ID: 16804062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
    Cameron NE; Cotter MA; Dines KC; Maxfield EK; Carey F; Mirrlees DJ
    Diabetologia; 1994 Jul; 37(7):651-63. PubMed ID: 7958535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.
    Hattori T; Matsubara A; Taniguchi K; Ogura Y
    Curr Eye Res; 2010 Feb; 35(2):146-54. PubMed ID: 20136425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N; Mizuno K; Makino M; Suzuki T; Yagihashi S
    Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst.
    Obrosova IG; Mabley JG; Zsengellér Z; Charniauskaya T; Abatan OI; Groves JT; Szabó C
    FASEB J; 2005 Mar; 19(3):401-3. PubMed ID: 15611153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.
    Coppey LJ; Gellett JS; Davidson EP; Dunlap JA; Lund DD; Salvemini D; Yorek MA
    Br J Pharmacol; 2001 Sep; 134(1):21-9. PubMed ID: 11522593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D; Mirrlees DJ; Harrison HE; Earl DC
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.